Please try another search
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Faheem Hasnain | 63 | 2015 | Co-Founder, CEO, President & Chairman |
Russell J. Cox | 60 | 2018 | Independent Director |
Skye Drynan | 48 | 2024 | Independent Director |
Sandra Milligan | 60 | 2021 | Independent Director |
Steven D. Nathan | 65 | 2024 | Independent Director |
Thomas O. Daniel | 70 | 2018 | Lead Independent Director |
John D. Quisel | 53 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review